By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
So do you not think that JAK1 "specificity" is an appropriate choice for patient who fails JAK1-3 drug (i.e. try upa in a tofa failure)?